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E. Clinical Drugs 
F. Advantages & disadvantages 
• HER2
A. Structure
• Statistical Data 
• HER2-Nanobody complex
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Hamers-casterman In 1993 , In Brussels (1)
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Timeline Of Nanobody
Separated from serum via Protein A and Protein 
G chromatography 1993
Muyldermans & co-workersIn 1994, sequence
The Term ‘Nanobodies’ (Ablynx®)
In camels (Camelus dromedarius & Camelus
bactrianus)
Llama (Lama glama & Lama guanicoe)




Nurse shark (Ginglymostoma cirratum)
Wobbegong (Orectolobus maculates)




3. Labeled With Multiple Dyes
4. Commercially Available
1. Not Recombinant; Require Animal Sacrifice 
2. Poor Tissue Penetration
3. Less Resolution Due To Larger Label Displacement
4. Require Separate Incubation Of 1° & 2°
5. Must Use Different Species And/Or Different IgG
Subclasses Of 1° For Multi-color Staining
6. Can Be Expensive
Nanobodies 1. Recombinant; do not require 
animal sacrifice
2. Good tissue penetration
3. Can be labeled with multiple 
dyes
4. Greater resolution due to 
lower label displacement
5. 2° incubation can be skipped 
by pre-binding to 1°
1. Monovalent
2. Monoclonal
3. Only Anti- Rabbit And -Mouse Versions Are 
Currently Available
4. Not Commercially Available
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Key features Key benefits
1. Small size (~15 kDa)  
2. Not Contain A Light Chain & CH1 Domain 
Size 3*3*4 nm (Penetrate  into per meabilized cell)
1. Four Conserved regions (FRs)
2. Three Connecting regions CDRs 
3. Nine β-strands
1. Easily  produced in E. coli or yeast cells
2. Humanize By Modifying Few Residues In FR2 
without altering properties(2)
1. Very Soluble & Highly Stable
2. High Specificity & Affinity For Antigen & 
Thermal &  Conformational Stability
3. Homology with human VH , low immunogenicity
1. Bind a wide range of epitopes with affinities in the 
nm ,pm range
2. Resistant to the acidic environment of the stomach




























































































1. CDR3 human VH is 13 aa , Dromedaries 18 aa
2. 50 file pdb database









Immunization of one Llama on standard 
protocol ELISA to assess the titer 
II Plasma Cell Isolation SPIN® technology isolates plasma cells 
III Single Domain Library Construction
Single domain antibody genes are 
amplified to construct small libraries 
IV Expression and Screening
ELISA or functional assays make 
antibodies suitable for downstream work. 
V Production 



























































Nanobody Application  
Non-invasive In Vivo Imaging 
1. Nanobody For Molecular Imaging Of 
Cancer
1. In Nuclear Imaging
2. Nanobody-targeted Ultrasound
3. In Optical Imaging
Therapeutic Nanobodies Directed Against 
Extracellular Targets
1.  Nanobody-mediated Drug Delivery




2. Nanobodies Against Intracellular Targets: 
Tools To Identify New
Linked To Enzymes Or Fluorescent Proteins 
Antigen-targeting Molecules Inside Cells
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Head & Neck Cancers 
VEGF , HGF , EGFR
Venom Therapy
Aflatoxins In Agro-products 
Thrombotic Thrombocytopenic Purpura
Plasmodium Knowlesi Malaria Vector 22
Nanobody Application  
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Nanobody Application  
Clinical Drugs 
ATN-103 and PF-05230905 Anti-TNFα Nanobodies in Rheumatoid Arthritis
ALX-0081 and ALX-0681 Anti-vWF Nanobodies in Haematology And 
Thrombotic Disorders
ALX-0141 Anti-RANKL Nanobodies In Diseases Characterised
By Unwanted Bone Loss
ALX-0061 Anti-IL-6R Nanobodies in Rheumatoid Arthritis 
ALX-0651 Anti-CXCR4 Nanobodies in stem cell mobilisation




Advantages & Disadvantages 
Advantages Disadvantages





1. Yields, Mg From Bacteria Grown In 
Simple Shake Flasks
2. Eukaryotic Cell Lines And Plants
3. Facile Production In Microbial Hosts  





































• Through This Method Of Experimental Design For Process Optimization





5. Type Of Vector
6. Host Strain
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• 131I-labeled  sdAb : 
• Treat HER2-overexpressing cancer. 
• Anti-HER2 sdAb 2Rs15d  :
• Labeled with 131I using [131I]SGMIB and evaluated in vitro
• The structure of the 2Rs15d-HER2 complex :
1. X-ray crystallography 
2. Recognizes HER2 Domain 1 
3. Bound specifically to HER2+ cells (KD=4.74±0.39nM)
34
Nanobody-HER2 
• Success of future therapeutic sdAb :
• Reducing kidney retention of radiolabeled sdAbs
• anti-HER2 sdAb using the radiohalogen 131I 
• 2Rs15d radiolabeled with 131I via the residualizing prosthetic group N-succinimidyl 4-
Guanodinomethyl-3-[*I]benzoate ([*I]SGMIB)
• [*I]SGMIB was twofold:
• (i) rapidly clearing catabolites (reduce kidney dose of small radiolabeled biomolecules 
that are filtered via kidneys ) 
• (ii) the high pKa of its guanidino group interferes with the transport of labeled catabolites
out of lysosomes, thereby trapping the radioiodine in cancer cells 
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Determination of the HER2-2Rs15d complex crystal 
structure 
• Contribute to HER2 recognition interactions with HER2 are mediated by :
• 2Rs15d residues located in the (CDRs) 
• Equal number of aa located in (FRs)
• Interactions between 2Rs15d and HER2 domain I is presented in Supplementary Fig. 
S1D and Supplementary Table S2. 
• Binding affinity, 0 to 300 nM
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5my6 › Nanobody 2Rs15d 
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